IPS Biopharma AG is tackling one of the biggest challenges in cancer treatment: recurrence. Our phase 2 asset, IP‑001, can activate specific anti-tumor immunity following in situ tumor destruction, turning standard focal interventions into a potential catalyst for durable anti-cancer immunity.
Cooperation possibilities
Cooperation possibilities include investigating the potential of combination therapies, specifically, checkpoint inhibitors or other immune modulators that could benefit from IP-001-mediated immune priming with the whole cell repertoire of tumor antigens generating a de novo T cell population.
- https://immunophotonics.com
- Send an email
- Theresa Visarius
